FDAMA Allows Novel Genetic Tests To Be Regulated As 510(k)s - CDRH
This article was originally published in The Gray Sheet
Executive Summary
FDA will likely regulate most genetic tests through the premarket notification process and its related controls - including manufacturing, labeling, adverse event reporting and postmarket study controls, according to Center for Devices and Radiological Health officials.
You may also be interested in...
Nephrology Test Opportunity Drives Behrman Buy-Out Of Athena Diagnostics
Behrman Capital's agreement to purchase the Athena Diagnostics unit from Elan illustrates the private equity firm's commitment to commercializing Athena's esoteric nephrology testing capabilities
Nephrology Test Opportunity Drives Behrman Buy-Out Of Athena Diagnostics
Behrman Capital's agreement to purchase the Athena Diagnostics unit from Elan illustrates the private equity firm's commitment to commercializing Athena's esoteric nephrology testing capabilities
HHS Begs Novel Approach To Genetic Tests Pending FDA Authority Verdict
The HHS Secretary's Advisory Committee on Genetic Testing is planning on a final legal review decision from FDA on oversight and premarket review of genetic tests in time for its August meeting